The **TEAM-HF IDE trial** is a study to check how safe and effective a device called the HeartMate 3 LVAS is, compared to regular heart failure treatment. This trial focuses on people with severe heart problems who can still move around but have a high risk of getting worse. Heart failure is when your heart doesn't pump blood as well as it should. Some people with severe heart failure may be treated with a device called a **Left Ventricular Assist Device (LVAD)**, which helps the heart pump blood. This study wants to see if using the LVAD earlier can help patients live longer and feel better. **Key Points:** - The study will involve about 850 people worldwide, with some receiving the HeartMate 3 LVAS and others getting regular treatment. - Participation might require you to have a small sensor placed to measure a specific type of blood pressure called **mean Pulmonary Artery Pressure (PAP)**. - You must be willing to possibly receive the HeartMate 3 LVAS if you are selected for that group. This trial is important to understand if early use of LVAD can help patients who are not on a constant medication called an inotrope.